论文部分内容阅读
1型人类免疫缺陷病毒 ( HIV- 1 )亚单位疫苗成功开发的关键在于提高其免疫原性 ,成功的佐剂不仅比现行佐剂更能增强免疫原性 ,而且还必须能减少最佳免疫原性所需的免疫原剂量。作者报告了 HIV- 1包膜亚单位掺入活化的 α2 -巨球蛋白 ( α2 M* ) ,在与含佐剂单磷酰脂质 A的鲨烯
The key to successful development of the human immunodeficiency virus type 1 (HIV-1) subunit vaccine is to improve its immunogenicity. Successful adjuvants not only enhance the immunogenicity compared to current adjuvants, but also reduce the optimal immunogen The required amount of immunogen. The authors report that incorporation of the HIV-1 envelope subunit into activated α2-macroglobulin (α2 M *) has been shown to be associated with squalene containing adjuvant monophosphoryl lipid A